DexCom, Inc. (DXCM) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
DexCom, Inc.
Address
6340 Sequence Drive
San Diego, CA 92121
United States of America (the)
Phone
858 200 0200
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
11050
First IPO Date
April 14, 2005
Key Executives
| Name | Title | Pay | Year Born |
| Jacob Steven Leach | President, CEO & Director | 2.05M | 1978 |
| Peter Simpson | Executive Vice President & Chief Technology Officer | 423,920 | N/A |
| Sadie Stern | Executive VP, Chief People & Culture Officer | 1.01M | 1975 |
| Jon Coleman | Executive Vice President & Chief Commercial Officer | 1.01M | 1964 |
| Michael Brown | Executive VP, Chief Legal & Compliance Officer | 1.1M | 1970 |
| Jereme Sylvain | Executive VP, CFO, COO & Chief Accounting Officer | 1.14M | 1980 |
| Kevin Ronald Sayer | Executive Chairman of the Board | 2.43M | 1958 |
| Matthew Dolan | Executive Vice President of Strategy & Corporate Development | 0 | 1981 |
| Christine Pospisil | Director of Medical Science & Education | 0 | N/A |
| Sean Christensen | Vice President of Finance and Investor Relations | 0 | N/A |
| Keri Leone | Senior Director of Global Medical Science & Education | 0 | N/A |
Description
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
